CLIP2

Across TCGA pan-cancer cohorts, CLIP2 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of CLIP2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where CLIP2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types CLIP2 is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.

CCRCC, LUAD, and HNSC are the cancer types where CLIP2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CLIP2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	All	+0.457	<.001	9	view →
LUAD	Male	III,IV	−0.433	<.001	9	view →
HNSC	Male	IV	+0.375	<.001	8	view →
LSCC	All	III,IV	−0.328	<.001	8	view →
PDAC	All	All	−0.174	<.001	8	view →
COAD	All	All	−0.078	.004	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

CLIP2–CCRCC

Open the CCRCC breakdown →